select a format

Single User License
USD 2995 INR 195034
Site License
USD 5990 INR 390069
Corporate User License
USD 8985 INR 585103


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Dyslipidemia-Current and Future Players

Dyslipidemia-Current and Future Players

  • Products Id :- GDHC1056FPR
  • |
  • Pages: 120
  • |
  • May 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Dyslipidemia-Current and Future Players


GlobalData has released its pharma report, "Dyslipidemia-Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dyslipidemia Market. The report identifies and analyses the key companies shaping and driving the global Dyslipidemia market. The report provides insight into the competitive Dyslipidemia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


Investigation of current and future market competition for Dyslipidemia

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of Dyslipidemia sector through market impact analysis, future market scenario and company analysis

Reasons To Buy

Gain a high level view of the trends shaping and driving Dyslipidemia market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What's the next big thing in the global Dyslipidemia market landscape? Identify, understand and capitalize

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Catalyst 6

2.2 Related Reports 7

2.3 Upcoming Related Reports 8

3 Market Outlook 9

3.1 Global Markets 9

3.1.1 Forecast 9

3.1.2 Drivers and Barriers-Global Issues 18

4 Current and Future Players 22

4.1 Overview 22

4.2 Trends in Corporate Strategy 27

4.3 Company Profiles 29

4.3.1 AbbVie 29

4.3.2 Aegerion Pharmaceuticals, Inc. 31

4.3.3 Amarin 33

4.3.4 Amgen 35

4.3.5 AstraZeneca 37

4.3.6 Cerenis Therapeutics Inc. 40

4.3.7 Daiichi Sankyo 42

4.3.8 Dezima Pharma 44

4.3.9 Eli Lilly 46

4.3.10 Esperion Therapeutics, Inc. 49

4.3.11 Genzyme 51

4.3.12 GlaxoSmithKline 53

4.3.13 Merck & Co. 55

4.3.14 Pfizer 58

4.3.15 Regeneron Pharmaceuticals, Inc. 60

4.3.16 Sanofi 62

5 Appendix 66

5.1 Bibliography 66

5.2 Abbreviations 94

5.3 Methodology 102

5.4 Forecasting Methodology 102

5.4.1 Diagnosed Dyslipidemia Patients 102

5.4.2 Percent Drug-Treated Patients 103

5.4.3 Drugs Included in Each Therapeutic Class 103

5.4.4 Launch and Patent Expiry Dates 104

5.4.5 General Pricing Assumptions 105

5.4.6 Individual Drug Assumptions 106

5.4.7 Generic Erosion 113

5.4.8 Pricing of Pipeline Agents 113

5.5 Physicians and Specialists Included in this Study 115

5.6 About the Authors 117

5.6.1 Analyst 117

5.6.2 Therapy Area Director 117

5.6.3 Epidemiologist 118

5.6.4 Global Head of Healthcare 118

5.7 About GlobalData 119

5.8 Disclaimer 119

1.2 List of Figures

Figure 1: Global Sales for Dyslipidemia by Country, 2013-2023 14

Figure 2: Global Sales for Dyslipidemia by Drug Class, 2013-2023 15

Figure 3: Global Sales Forecast for PCSK9 mAbs, 2015-2023 16

Figure 4: Projected Global Sales of Dyslipidemia Drugs by Year, 2013-2023 17

Figure 5: Global Sales of Branded Products for Dyslipidemia by Company, 2013-2023 26

Figure 6: Company Portfolio Gap Analysis in Dyslipidemia, 2013-2023 27

1.1 List of Tables

Table 1: Global Sales Forecasts (USD m) for Dyslipidemia, 2013-2023 12

Table 2: Dyslipidemia Market-Drivers and Barriers, 2014 18

Table 3: Key Companies in the Dyslipidemia Market in the 8MM, 2014 25

Table 4: AbbVie's Dyslipidemia Portfolio Assessment, 2014 30

Table 5: Aegerion's Dyslipidemia Portfolio Assessment, 2014 32

Table 6: Amarin's Dyslipidemia Portfolio Assessment, 2014 34

Table 7: Amgen's Dyslipidemia Portfolio Assessment, 2014 36

Table 8: AstraZeneca's Dyslipidemia Portfolio Assessment, 2014 39

Table 9: Cerenis' Dyslipidemia Portfolio Assessment, 2014 41

Table 10: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2014 43

Table 11: Dezima's Dyslipidemia Portfolio Assessment, 2014 45

Table 12: Eli Lilly's Dyslipidemia Portfolio Assessment, 2014 47

Table 13: Esperion's Dyslipidemia Portfolio Assessment, 2014 50

Table 14: Genzyme's Dyslipidemia Portfolio Assessment, 2014 52

Table 15: GlaxoSmithKline's Dyslipidemia Portfolio Assessment, 2014 54

Table 16: Merck's Dyslipidemia Portfolio Assessment, 2014 57

Table 17: Pfizer's Dyslipidemia Portfolio Assessment, 2014 59

Table 18: Regeneron's Dyslipidemia Portfolio Assessment, 2014 61

Table 19: Sanofi's Dyslipidemia Portfolio Assessment, 2014 64

Table 20: Key Launch Dates 104

Table 21: Key Patent Expiries 104

Table 22: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 116

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]


Aegerion Pharmaceuticals, Inc.




Cerenis Therapeutics Inc.

Daiichi Sankyo

Dezima Pharma

Eli Lilly

Esperion Therapeutics, Inc.



Merck & Co.


Regeneron Pharmaceuticals, Inc.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]